MAP2 and Alzheimer disease: Although the iPSCs technology has opened a new window for AD treatment, and newly generated neurons from iPSCs of familial AD patients also expressed MAP2 and β III-tubulin, formed functional synaptic contacts, and exhibited normal electrophysiological activity in vitro, these neurons showed similar cellular pathological feature with those in AD patients [42].